跳至主要内容
临床试验/JPRN-UMIN000022533
JPRN-UMIN000022533招募中2 期

A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease - The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's Disease(DATSZ-PD study)

Osaka Redcross Hospital Wakayama Prefectural Medical College0 个研究点目标入组 180 人开始时间: 2016年6月1日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
55years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Those who matched the following conditions should be excluded. 1). Those who had been treated with the anti-parkinsonian drugs except levodopa/DCI for more than 1month. 2).Those who are in pregnancy, or possible to be pregnant or those who are in the breast-feeding. 3) Those who have taken antidepressant and/or anti-psychotic drugs. 4) Those who have a history of stroke and cerebrovascular disorders. 5) Those who had a history of epilepsy or those who are in treatment of epilepsy 6) Those who have a history of alcohol intoxication, or have the treatment for alcoholic abuse 7) Those who have severe comorbidity( liver dysfunction, renal dysfunction and endocrinological disorders). 8) Those who have a familial history of Parkinson's disease 9) Those who have a history of allergic reaction with 123I- ioflupane.

研究者

发起方
Osaka Redcross Hospital Wakayama Prefectural Medical College

相似试验

A comparative randomized study for the evaluation of... | 临床试验